The Society for Immunotherapy of Cancer (SITC) to Hold Press Briefing on Nine Abstracts to be Presented at 37^th Annual Meeting

The Society for Immunotherapy of Cancer (SITC) invites you to attend the virtual press briefing of the society’s 37^th Annual Meeting (SITC 2022) beginning at 11:30 a.m. EST on Tuesday, Nov. 8, 2022.

The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research. Regular and late-breaking abstracts are embargoed until 8 a.m. EST, Nov. 7, 2022. Data shared during the presentation is embargoed until that date unless otherwise stated during the press briefing. For more information, please review the SITC 2022 Media Policy.

Read More >>

Latest Press Releases

1/27/23 –FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

11/11/22 –FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer

11/10/22 –FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer

11/3/22 –SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting

11/2/22 –SITC 2022 Late-Breaking Abstracts Announced

10/26/22 –FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

10/25/22 – FDA Approves Tremelimumab in Combination with Durvalumab for unresectable hepatocellular carcinoma

10/7/22 – The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology

10/5/22 – Black and African American Professionals Discuss Barriers in Biomedical Field

9/8/22 – Oncology News Burst from FDA: durvalumab

8/30/22– SITC Announces Annual Award Recipients

8/11/22– SITC Forward Fund Announces 2022 Fellowships and Tech Award Recipients

7/12/2022 – SITC to Convene Oncology Leaders to Address Crisis in Clinical Research at Virtual Summit

5/18/22 – SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37^th Annual Meeting

5/10/22 – SITC’s Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology

4/26/22 – Cancer Researchers to Rock Buddy Guy’s Legends for One Night Only

3/9/22 – Oncology News Burst from FDA: Nivolumab

1/13/22 – SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations

SITC Communications
communications@sitcancer.org
+1 414-271-2456